SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement With FDA For Phase 3 Study Evaluating Oral Ibrexafungerp For Prevention Of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)
Benzinga Newsdesk